Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
| October 22, 2024
Read More
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
| September 26, 2024
Read More
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
| September 23, 2024
Read More
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
| September 4, 2024
Read More
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
| August 28, 2024
Read More
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
| August 13, 2024
Read More
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
| July 11, 2024
Read More
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
| June 13, 2024
Read More
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
| May 28, 2024
Read More
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
| May 13, 2024
Read More
Blog Navigation
Contact Us
To learn more about Vivani or LIBERATE-1, the upcoming First-in-Human trial of our long-term GLP-1 implant, please fill out the form.